Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$10.9 million.

  • Insight Molecular Diagnostics' Net Income towards Common Stockholders rose 1955.83% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 12211.93%. This contributed to the annual value of -$61.0 million for FY2024, which is 198615.86% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Net Income towards Common Stockholders of -$10.9 million as of Q3 2025, which was up 1955.83% from -$9.7 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Net Income towards Common Stockholders' 5-year high stood at $4899.0 during Q1 2023, with a 5-year trough of -$45.2 million in Q4 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$9.7 million (2022), whereas its average is -$13.6 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Net Income towards Common Stockholders surged by 10004.76% in 2023, and later crashed by 19064909.17% in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Net Income towards Common Stockholders (Quarter) stood at -$35.9 million in 2021, then decreased by 25.97% to -$45.2 million in 2022, then skyrocketed by 85.21% to -$6.7 million in 2023, then plummeted by 402.87% to -$33.6 million in 2024, then surged by 67.72% to -$10.9 million in 2025.
  • Its last three reported values are -$10.9 million in Q3 2025, -$9.7 million for Q2 2025, and -$6.7 million during Q1 2025.